Vogler Sabine, Windisch Friederike
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (Austrian National Public Health Institute/GÖG), 1010 Vienna, Austria.
Department of Health Care Management, Technische Universität Berlin, 10623 Berlin, Germany.
Antibiotics (Basel). 2022 Jul 22;11(8):987. doi: 10.3390/antibiotics11080987.
Point-of-care diagnostic tests for community-acquired acute respiratory tract infections (CA-ARTI) can support doctors by improving antibiotic prescribing. However, little is known about health technology assessment (HTA), pricing and funding policies for CA-ARTI diagnostics. Thus, this study investigated these policies for this group of devices applied in the outpatient setting in Europe. Experts from competent authority responded to a questionnaire in Q4/2020. Information is available for 17 countries. Studied countries do not base their pricing and funding decision for CA-ARTI diagnostics on an HTA. While a few countries impose price regulation for some publicly funded medical devices, the prices of CA-ARTI diagnostics are not directly regulated in any of the surveyed countries. Indirect price regulation through public procurement is applied in some countries. Reimbursement lists of medical devices eligible for public funding exist in several European countries, and in some countries these lists include CA-ARTI diagnostics. In a few countries, the public payer funds the health professional for performing the service of conducting the test. Given low levels of regulation and few incentives, the study findings suggest room for strengthening pricing and funding policies of CA-ARTI diagnostics to contribute to increased acceptance and use of these point-of-care tests.
用于社区获得性急性呼吸道感染（CA-ARTI）的即时诊断测试可以通过改善抗生素处方来为医生提供支持。然而，对于CA-ARTI诊断的卫生技术评估（HTA）、定价和资助政策却知之甚少。因此，本研究调查了欧洲门诊环境中应用的这类设备的相关政策。主管部门的专家在2020年第四季度对一份问卷进行了回复。有17个国家提供了相关信息。被研究国家在CA-ARTI诊断的定价和资助决策中并未依据HTA。虽然有几个国家对一些公共资助的医疗设备实施价格监管，但在任何一个被调查国家，CA-ARTI诊断的价格都没有受到直接监管。一些国家通过公共采购实施间接价格监管。几个欧洲国家存在符合公共资助条件的医疗设备报销清单，在一些国家，这些清单包括CA-ARTI诊断。在少数国家，公共支付方为卫生专业人员进行测试服务提供资金。鉴于监管水平较低且激励措施较少，研究结果表明有空间加强CA-ARTI诊断的定价和资助政策，以促进这些即时诊断测试的接受度和使用率的提高。
